Evaxion Biotech A/S (EVAX)
|Net Income (ttm)||-14.27M|
Evaxion Biotech Announces Filing of Registration Statement in the U.S. for Proposed Initial Public Offering of Securities
COPENHAGEN, Denmark, Jan. 08, 2021 -- Evaxion Biotech A/S (the “Company” or “Evaxion”), a clinical-stage biotechnology company...
Evaxion Biotech, a Danish Phase 1/2 biotech using AI to develop immuno-oncology therapies, filed on Friday with the SEC to raise up to $35 million in an initial public offering.
Evaxion Biotech A/S has filed to go public with an IPO on the NASDAQ.
First Patient Dosed in Melanoma Vaccine Candidate Study With Checkpoint Inhibitors — Precision Vaccinations
Copenhagen-based Evaxion Biotech announced the dosing of the first patient in a Phase I/IIa clinical trial of its adjuvant immunotherapy EVX-02, combined with checkpoint inhibitors in patients...
Evaxion Biotech is a clinical-stage AI-immunology™ platform company using our proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections. Drug discovery and clinical development using historically prevailing techniques is a long, costly process with a high attrition rate. We believe our proprietary AI-immun... [Read more...]
|IPO Date |
Feb 4, 2021
Lars Staal Wegner, MD
|Stock Exchange |
|Ticker Symbol |